PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
May 16, 2023 11:37 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023 18:52 ET
|
PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
April 25, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
April 20, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash...
PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules
April 11, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of...
PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences
March 02, 2023 08:35 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and...
PharmAla Biotech Completes Annual General Meeting
March 01, 2023 08:00 ET
|
PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
Patent Application Published for PharmAla Biotech’s MDMA Analogs
February 23, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6...
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
February 14, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that, in the wake of a landmark decision by the...
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
February 06, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of...